Evonik plans $27M expansion of German API production sites

Evonik has announced a €25 million ($27 million) first stage of a long-term program to expand capacity at its Dossenheim and Hanau facilities in Germany for contract manufacturing of active pharmaceutical ingredients and advanced intermediates. The first stage is scheduled for completion by mid-2021, with the entire project expected by 2024.

“The COVID-19 pandemic has amplified the focus of many pharmaceutical companies to have European-based manufacturing sites that can support the production of their life-saving drug products for reliable supply to regional healthcare markets.”manufacturingchemist.com

• 1 source
• manufacturingchemist.comEvonik plans $27m expansion of German API productionDesign, Build Ingredients PharmaceuticalMay 5, 2020

Summarized from public sources; check the original articles before acting on it.